Skip to main content
DCOY
NASDAQ Life Sciences

Decoy Therapeutics Reports Q2 Loss, Going Concern Warning, and Nasdaq Delisting Risk

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$3.6
Mkt Cap
$2.125M
52W Low
$3.51
52W High
$106.2
52W Position info
2.6% above low
Off High info
97% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

DCOY is trading near its 52-week low of $3.51 (2.6% above the low) on light trading volume (0.1× avg).

Summary

Decoy Therapeutics reported a $4.6 million net loss for H1 2026, warned of going concern doubts, and disclosed a new Nasdaq delisting risk. The stock trades near its 52-week low.


Key Events · Earnings and Guidance · DCOY

  • Going Concern Warning

    The company states there is substantial doubt about its ability to continue as a going concern, with cash of $8.3 million as of June 30, 2026, expected to fund operations only into late 2026.

  • Nasdaq Delisting Risk

    A new risk factor discloses that if the SEC approves Nasdaq's proposed $5 million market value standard, Decoy's common stock could be imminently delisted because its market value is below the threshold.

  • H1 2026 Net Loss

    Net loss for the six months ended June 30, 2026 was $4.6 million, compared to $2.7 million in the prior year period, driven by increased R&D spending on the IMP3ACT platform.

  • Private Placement Details

    The 10-Q confirms the June 29, 2026 private placement raised $3.5 million upfront at $5.91 per share, with milestone warrants potentially adding up to $17.5 million more if exercised.


Analysis · DCOY · Life Sciences

Decoy Therapeutics' 10-Q reveals a $4.6 million net loss for the first half of 2026, cash of $8.3 million, and a going concern warning stating substantial doubt about its ability to continue operations. The company also disclosed a new risk factor regarding Nasdaq's proposed $5 million market value standard, which could lead to imminent delisting if approved. The stock trades near its 52-week low at $3.60, and the company's market cap is only about $2.1 million, making the delisting risk acute.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, DCOY was trading at $3.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1M. The 52-week trading range was $3.51 to $106.20. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

DCOY - Latest Insights

DCOY
Nov 13, 2026, 4:45 PM EST
Filing Type: S-3
Importance Score:
8
Price at Filing: $0.9752
Real-time Price: $0.930 info
Change: -$0.0452 (-5%) info
Market Cap: $2.326M info
DCOY
Nov 12, 2026, 6:31 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $1.06
Real-time Price: $0.930 info
Change: -$0.125 (-12%) info
Market Cap: $2.326M info
DCOY
Nov 12, 2026, 4:21 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.06
Real-time Price: $0.930 info
Change: -$0.125 (-12%) info
Market Cap: $2.326M info
DCOY
Oct 16, 2026, 4:07 PM EDT
Filing Type: 424B3
Importance Score:
7
Price at Filing: $1.17
Real-time Price: $0.930 info
Change: -$0.240 (-21%) info
Market Cap: $2.326M info
DCOY
Oct 07, 2026, 4:59 PM EDT
Filing Type: S-1
Importance Score:
7
Price at Filing: $1.60
Real-time Price: $0.930 info
Change: -$0.6686 (-42%) info
Market Cap: $2.326M info